Study of AST-3424 for advanced liver cancer with high AKR1C3
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called AST-3424 in people with advanced liver cancer that has gotten worse after prior treatment. It is for those whose tumor cells have high levels of a protein called AKR1C3, which the drug targets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that has grown after at least one previous treatment, including immunotherapy.
- Your tumor tissue shows high levels of a protein called AKR1C3.
- Your liver function is relatively good (Child-Pugh class A or B, score 7 or less).
- You are able to take care of yourself (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan, and your expected survival is at least 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ACE723, which is designed to specifically attack liver cancer cells while sparing healthy cells. It is for people with advanced liver cancer that has not responded to or has worsened after standard treatments that included immunotherapy.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial tests regorafenib, a targeted therapy, for people with advanced liver cancer that progressed after first-line immunotherapy. It aims to slow tumor growth and may offer a new option when standard treatment stops working.
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
This trial tests a new drug, regorafenib, for people with liver cancer that cannot be removed by surgery and who have already tried lenvatinib. The goal is to see if regorafenib can help control the cancer after lenvatinib stops working or causes too many side effects.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.